Literature DB >> 8866773

How to distinguish between the neuroleptic-induced deficit syndrome, depression and disease-related negative symptoms in schizophrenia.

T R Barnes1, M A McPhillips.   

Abstract

A major challenge in the clinical assessment of schizophrenia is the differentiation between depressive features, negative symptoms and neuroleptic side effects, including the adverse subjective experiences associated with this medication. The problems include the degree of symptom overlap, and the lack of precise operational definitions, particularly for negative symptoms and the putative, neuroleptic-induced deficit syndrome. The diagnostic process is further confounded by the need to discriminate between primary negative symptoms as persistent, enduring deficits, and social and emotional withdrawal secondary to positive symptoms, or related to depressive features or drug effects such as sedation and the bradykinesia component of parkinsonism. To distinguish between these elements is likely to require careful observation of patients with schizophrenia, over time, by trained raters using appropriate rating scales for depression and negative symptoms that are sensitive to change. Ratings of patients' subjective experiences regarding mood and awareness of behavioural and cognitive deficits should also be included. The associations between the subjective data and the objective ratings of depression, negative symptoms and drug side effects may help with clinical discrimination in these areas of dysfunction and with the refinement of their phenomenological descriptions.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8866773

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  5 in total

1.  Self-Evaluation of Negative Symptoms: A Novel Tool to Assess Negative Symptoms.

Authors:  Sonia Dollfus; Cyril Mach; Rémy Morello
Journal:  Schizophr Bull       Date:  2015-11-12       Impact factor: 9.306

2.  GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats.

Authors:  Ajaykumar N Sharma; Sagar S Ligade; Jay N Sharma; Praveen Shukla; Khalid M Elased; James B Lucot
Journal:  Metab Brain Dis       Date:  2014-07-15       Impact factor: 3.584

3.  Relations between movement disorders and psychopathology under predominantly atypical antipsychotic treatment in adolescent patients with schizophrenia.

Authors:  Stefan Gebhardt; Fabian Härtling; Markus Hanke; Frank M Theisen; Richard von Georgi; Phillip Grant; Markus Mittendorf; Matthias Martin; Christian Fleischhaker; Eberhard Schulz; Helmut Remschmidt
Journal:  Eur Child Adolesc Psychiatry       Date:  2007-09-14       Impact factor: 4.785

4.  Kinematic analysis of facial behaviour in patients with schizophrenia under emotional stimulation by films with "Mr. Bean".

Authors:  Georg Juckel; R Mergl; A Prässl; P Mavrogiorgou; H Witthaus; H J Möller; U Hegerl
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-04       Impact factor: 5.270

Review 5.  Augmentation with antidepressants in schizophrenia treatment: benefit or risk.

Authors:  Ye-Meng Mao; Ming-Dao Zhang
Journal:  Neuropsychiatr Dis Treat       Date:  2015-03-16       Impact factor: 2.570

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.